Tag Archives: VRX

H.C. Wainwright Upgrades Valeant Pharm International (VRX) to Buy

According to The Fly, in a new note to investors today, an analyst has provided a rating update for Valeant Pharm International (VRX – Research Report). Ram Selvaraju, an analyst with H.C. Wainwright, has upgraded their rating on VRX to

Valeant Pharm International (VRX) Gets a Buy Rating from Cantor Fitzgerald

According to The Fly, a Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Valeant Pharm International (VRX

TD Securities Downgrades Valeant Pharma to Hold

In a report released today, Lennox Gibbs from TD Securities downgraded Valeant Pharma (NYSE: VRX) to Hold. The company’s shares closed yesterday at $24.72. According to TipRanks.com, Gibbs is ranked #4591 out of 4829 analysts. Currently, the analyst consensus on

H.C. Wainwright Reiterates Their Hold Rating on Valeant Pharma

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Valeant Pharma (NYSE: VRX), with a price target of $20. The company’s shares closed yesterday at $23.56. According to TipRanks.com, Selvaraju is a 3-star analyst

H.C. Wainwright Keeps a Hold Rating on Valeant Pharma

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Valeant Pharma (NYSE: VRX), with a price target of $20. The company’s shares closed yesterday at $20.25. Selvaraju commented: “Exchange NYSE Value (M) $31,421.0 Market

H.C. Wainwright Sticks to Their Hold Rating for Valeant Pharma

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Valeant Pharma (NYSE: VRX) today and set a price target of $16. The company’s shares closed yesterday at $16.95. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars